UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Associations of TP53- and/or PIK3CA mutated HR-positive, invasive ductal breast cancers (IDBC) of the METABRIC collection with distant recurrence risk (DRR) and time-to-recurrence (TTR)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12542-e12542

Hackl, Wolfgang

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of B-score for predicting joint replacement in the context of osteoarthritis phenotypes: Data from the osteoarthritis initiative

Osteoarthritis and cartilage open, 2024-06, Vol.6 (2), p.100458-100458, Article 100458

2024

Link zum Volltext

Verfügbarkeit prüfen

Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study

Annals of oncology, 2020-10, Vol.31 (10), p.1359-1365

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-08-06: A novel integrated, clinical-pathologic and genomic classification method segregates early from late relapsing invasive ductal luminal breast cancers (IDLBC) of the METABRIC study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-06

2019

Link zum Volltext

Verfügbarkeit prüfen

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.112-112

2012

Link zum Volltext

Verfügbarkeit prüfen

986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study

Annals of oncology, 2022-09, Vol.33, p.S1003

2022

Link zum Volltext

Verfügbarkeit prüfen

96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1

Annals of oncology, 2021-05, Vol.32, p.S64

2021

Link zum Volltext

Verfügbarkeit prüfen

P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S313

2023

Link zum Volltext

Verfügbarkeit prüfen

Are waterborne astrovirus implicated in acute digestive morbidity (E.MI.R.A. study)?

Journal of clinical virology, 2003-05, Vol.27 (1), p.74-82

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-14-02: Analysis of DRFI and OS of HR-positive, HER2-negative breast cancer patients treated on the BIG1-98 study, classified according to a novel, integrated, clinical-pathologic and genomic classification method

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-14-02

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S1-S1-10

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Pi3K Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)

Annals of oncology, 2014-09, Vol.25, p.iv150

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-14

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-10-07

2012

Link zum Volltext

Verfügbarkeit prüfen

P3-16-01: Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P3-P3-16-01

2011

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3003-3003

2010

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3005-3005

2010

Link zum Volltext

Verfügbarkeit prüfen

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3043-3043

2011

Link zum Volltext

Verfügbarkeit prüfen

Health risks and parasitical quality of water

Journal - American Water Works Association, 2003-05, Vol.95 (5), p.162-172

2003

Link zum Volltext

Verfügbarkeit prüfen

451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv150-iv150

2014

Link zum Volltext

Verfügbarkeit prüfen

Molecular, biologic and clinical profiling of chromosomal instable, hormone receptor positive, invasive ductal breast cancer (IDBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12524-e12524

Demanse, David

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

Clinical cancer research, 2015-02, Vol.21 (4), p.730-738

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.285-298

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.508-508

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3003-3003

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(5)
Humans
(4)
Life Sciences & Biomedicine
(4)
Aged
(3)
Middle Aged
(3)
Oncology
(3)
Adult
(2)
Aged, 80 And Over
(2)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Breast Neoplasms - Drug Therapy
(2)
Cancer
(2)
Diarrhea
(2)
Dose-Response Relationship, Drug
(2)
Drinking Water
(2)
Female
(2)
Infectious Diseases
(2)
Male
(2)
Morbidity
(2)
Neoplasms - Drug Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Associations of TP53- and/or PIK3CA mutated HR-positive, invasive ductal breast cancers (IDBC) of the METABRIC collection with distant recurrence risk (DRR) and time-to-recurrence (TTR)

Prognostic value of B-score for predicting joint replacement in the context of osteoarthritis phenotypes: Data from the osteoarthritis initiative

Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study

Abstract P3-08-06: A novel integrated, clinical-pathologic and genomic classification method segregates early from late relapsing invasive ductal luminal breast cancers (IDLBC) of the METABRIC study

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study

96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1

P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

Are waterborne astrovirus implicated in acute digestive morbidity (E.MI.R.A. study)?

Abstract P4-14-02: Analysis of DRFI and OS of HR-positive, HER2-negative breast cancer patients treated on the BIG1-98 study, classified according to a novel, integrated, clinical-pathologic and genomic classification method

Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study

Phase I Study of the Pi3K Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)

P3-16-01: Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy

Health risks and parasitical quality of water

451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST)

Molecular, biologic and clinical profiling of chromosomal instable, hormone receptor positive, invasive ductal breast cancer (IDBC)

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors

Suchergebnisse filtern